Skip to main content
Premium Trial:

Request an Annual Quote

Josh Bilenker

Josh Bilenker has resigned from Roka Bioscience's board, citing demands on his time and other professional commitments. His resignation is effective immediately. Bilenker, who is the CEO of and a director at Loxo Oncology, joined Roka's board in early 2012 and served on its audit committee.